Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

roche pharmaceuticals a/s - levodopum inn; benserazidum hýdróklóríð - lausnartafla - 100 mg/25 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

roche pharmaceuticals a/s - levodopum inn; benserazidum hýdróklóríð - lausnartafla - 50 mg/12,5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil denmark aps - nicotinum - munnholsúði, lausn - 1 mg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil denmark aps - nicotinum - munnholsúði, lausn - 1 mg/skammt

Evrópusambandið - íslenska - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. sjá kafla 4. 4 og 5.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lyfjaver ehf. - nicotinum - munnholsúði, lausn - 1 mg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

heilsa ehf. - nicotinum - munnholsúði, lausn - 1 mg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil denmark aps - nicotinum - forðaplástur - 10 mg/16 klst.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil denmark aps - nicotinum - forðaplástur - 15 mg/16 klst.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil denmark aps - nicotinum - forðaplástur - 25 mg/16 klst.